Conventional and advanced imaging in neuromyelitis optica

American Journal of Neuroradiology

Volumn 35, Issue 8, 2014, Pages 1458-1466

  Barnett, Y ^a,b,c   Sutton, I J ^c   Ghadiri, M ^b   Masters, L ^b   Zivadinov, R ^d   Barnett, Michael H ^a,b  

^a Sydney Neuroimaging Analysis Centre   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY; AUTOANTIBODY; GADOLINIUM; IMMUNOGLOBULIN G ANTIBODY;

ANGIOGRAPHY; ANTIBODY BLOOD LEVEL; ASTROCYTE; AUTOIMMUNITY; BRAIN AQUEDUCT; BRAIN CORTEX LESION; BRAIN FOURTH VENTRICLE; BRAIN THIRD VENTRICLE; CENTRAL GRAY MATTER; CORPUS CALLOSUM; DIFFERENTIAL DIAGNOSIS; DIFFUSION TENSOR IMAGING; DURAL ARTERIOVENOUS FISTULA; FRACTIONAL ANISOTROPY; GRAY MATTER; HISTOGRAM; HUMAN; HYPOTHALAMUS; LATERAL BRAIN VENTRICLE; LONGITUDINALLY EXTENSIVE SPINAL CORD LESION; MYELOOPTIC NEUROPATHY; NERVE FIBER DEGENERATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OPTIC NERVE; PATHOGENESIS; PHENOTYPE; PYRAMIDAL TRACT; REVIEW; SARCOIDOSIS; SJOEGREN SYNDROME; SPINAL CORD LESION; SUSCEPTIBILITY WEIGHTED IMAGING; SYSTEMIC LUPUS ERYTHEMATOSUS; THALAMUS; VOXEL BASED MORPHOMETRY; WHITE MATTER; WHITE MATTER LESION; NEUROMYELITIS OPTICA; PROCEDURES; TRENDS;

HUMANS; NEUROIMAGING; NEUROMYELITIS OPTICA;

EID: 84907333937     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A3592     Document Type: Review

References (78)

1. Devic E. Myélite subaiguë compliquée de névrite optique. Bull Med (Paris) 1894;8:1033-34
2. Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-14 (Pubitemid 29442132)
3. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-12 (Pubitemid 39626806)
4. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202:473-77 (Pubitemid 41186945)
5. Barnett MH, Prineas JW, Buckland ME, et al. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler 2012;18:108-12
6. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002;125:1450-61 (Pubitemid 34755161)
7. Giovannoni G. To test or not to test: NMO-IgG and optic neuritis. Neurology 2008;70:2192-93
8. Kim W, Park MS, Lee SH, et al. Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity. Mult Scler 2010;16:1229-36
9. Kim W, Kim SH, Huh SY, et al. Brain abnormalities in neuromyelitis optica spectrum disorder. Mult Scler Int 2012;2012:735486
10. Matiello M, Lennon VA, Jacob A, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008;70:2197-200
11. Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006;59:566-69 (Pubitemid 43358081)
12. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-89 (Pubitemid 43958540)
13. Palace J, Leite MI, Nairne A, et al. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 2010;67:1016-17
14. Shimizu J, Hatanaka Y, Hasegawa M, et al. IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology 2010;75:1423-27
15. Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 2012;18:113-15
16. Nakamura M, Miyazawa I, Fujihara K, et al. Preferential spinal central gray matter involvement in neuromyelitis optica: an MRI study. J Neurol 2008;255:163-70
17. Filippi M, Rocca MA, Moiola L, et al. MRI and magnetization transfer imaging changes in the brain and cervical cord of patients with Devic's neuromyelitis optica. Neurology 1999;53:1705-10 (Pubitemid 29530343)
18. Filippi M, Rocca MA. MR imaging of Devic's neuromyelitis optica. Neurol Sci 2004;25(suppl 4):S371-73 (Pubitemid 39600435)
19. Pires CE, Silva CM, Lopes FC, et al. Brain MRI abnormalities in Brazilian patients with neuromyelitis optica. J Clin Neurosci 2012;19:969-74
20. Downer JJ, Leite MI, Carter R, et al. Diagnosis of neuromyelitis optica (NMO) spectrum disorders: is MRI obsolete? Neuroradiology 2012;54:279-85
21. Hinson SR, Romero MF, Popescu BF, et al. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A 2012;109:1245-50
22. Magaña SM, Matiello M, Pittock SJ, et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 2009;72:712-17
23. Delalande S, de Seze J, Fauchais AL, et al. Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore) 2004;83:280-91 (Pubitemid 39258414)
24. Schulz SW, Shenin M, Mehta A, et al. Initial presentation of acute transverse myelitis in systemic lupus erythematosus: demographics, diagnosis, management and comparison to idiopathic cases. Rheumatol Int 2012;32:2623-27
25. McKeon A, Lennon VA, Jacob A, et al. Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve 2009;39:87-90
26. Pittock SJ, Lennon VA, de SJ, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008;65:78-83
27. Kim SM, Waters P, Vincent A, et al. Sjögren's syndrome myelopathy: spinal cord involvement in Sjögren's syndrome might be a manifestation of neuromyelitis optica. Mult Scler 2009;15:1062-68
28. Trebst C, Raab P, Voss EV, et al. Longitudinal extensive transverse myelitis: it's not all neuromyelitis optica. Nat Rev Neurol 2011;7:688-98
29. Khanna S, Sharma A, Huecker J, et al. Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis. J Neuroophthalmol 2012;32:216-20
30. Li Y, Xie P, Lv F, et al. Brain magnetic resonance imaging abnormalities in neuromyelitis optica. Acta Neurol Scand 2008;118:218-25
31. McKeon A, Lennon VA, Lotze T, et al. CNS aquaporin-4 autoimmunity in children. Neurology 2008;71:93-100
32. Pittock SJ, Lennon VA, Krecke K, et al. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006;63:390-96
33. Cabrera-Gómez JA, Quevedo-Sotolongo L, Gonzalez-Quevedo A, et al. Brain magnetic resonance imaging findings in relapsing neuromyelitis optica. Mult Scler 2007;13:186-92 (Pubitemid 46592770)
34. Makino T, Ito S, Mori M, et al. Diffuse and heterogeneous T2-hyperintense lesions in the splenium are characteristic of neuromyelitis optica. Mult Scler 2013;19:308-15
35. Pittock SJ, Weinshenker BG, Lucchinetti CF, et al. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006;63:964-68 (Pubitemid 44036298)
36. Poppe AY, Lapierre Y, Melancon D, et al. Neuromyelitis optica with hypothalamic involvement. Mult Scler 2005;11:617-21 (Pubitemid 41387709)
37. Parratt JD, Prineas JW. Neuromyelitis optica: a demyelinating disease characterized by acute destruction and regeneration of perivascular astrocytes. Mult Scler 2010;16:1156-72
38. Wang F, Liu Y, Duan Y, et al. Brain MRI abnormalities in neuromyelitis optica. Eur J Radiol 2011;80:445-49
39. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120(pt 11):2059-69 (Pubitemid 27493740)
40. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302
41. Nakashima I, Fujihara K, Miyazawa I, et al. Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neurol Neurosurg Psychiatry 2006;77:1073-75 (Pubitemid 44338534)
42. Viegas S, Weir A, Esiri M, et al. Symptomatic, radiological and pathological involvement of the hypothalamus in neuromyelitis optica. J Neurol Neurosurg Psychiatry 2009;80:679-82
43. Nakajima H, Fujiki Y, Ito T, et al. Anti-aquaporin-4 antibody-positive neuromyelitis optica presenting with syndrome of inappropriate antidiuretic hormone secretion as an initial manifestation. Case Rep Neurol 2011;3:263-67
44. Baba T, Nakashima I, Kanbayashi T, et al. Narcolepsy as an initial manifestation of neuromyelitis optica with anti-aquaporin-4 antibody. J Neurol 2009;256:287-88
45. Suzuki K, Nakamura T, Hashimoto K, et al. Hypothermia, hypotension, hypersomnia, and obesity associated with hypothalamic lesions in a patient positive for the anti-aquaporin 4 antibody: a case report and literature review. Arch Neurol 2012;69:1355-59
46. Lu Z, Qiu W, Zou Y, et al. Characteristic linear lesions and longitudinally extensive spinal cord lesions in Chinese patients with neuromyelitis optica. J Neurol Sci 2010;293:92-96
47. Nakamura M, Misu T, Fujihara K, et al. Occurrence of acute large and edematous callosal lesions in neuromyelitis optica. Mult Scler 2009;15:695-700
48. Cabrera-Gomez JA, Kister I. Conventional brain MRI in neuromyelitis optica. Eur J Neurol 2012;19:812-19
49. Saiki S, Ueno Y, Moritani T, et al. Extensive hemispheric lesions with radiological evidence of blood-brain barrier integrity in a patient with neuromyelitis optica. J Neurol Sci 2009;284:217-19
50. Barnett MH, Sutton I. Neuromyelitis optica: not a multiple sclerosis variant. Curr Opin Neurol 2012;25:215-20
51. Bichuetti DB, Oliveira EM, Souza NA, et al. Neuromyelitis optica in Brazil: a study on clinical and prognostic factors. Mult Scler 2009;15:613-19
52. Ito S, Mori M, Makino T, et al. "Cloud-like enhancement" is a magnetic resonance imaging abnormality specific to neuromyelitis optica. Ann Neurol 2009;66:425-28
53. Banker P, Sonni S, Kister I, et al. Pencil-thin ependymal enhancement in neuromyelitis optica spectrum disorders. Mult Scler 2012;18:1050-53
54. McGraw CA, Swerdlow ML, Robbins MS. Acute reversible periependymal ventricular enhancement in neuromyelitis optica. Eur J Neurol 2012;19:e57-e58
55. Kister I, Herbert J, Zhou Y, et al. Ultrahigh-field MR (7T) imaging of brain lesions in neuromyelitis optica. Mult Scler Int 2013;2013:398259
56. Pichiecchio A, Tavazzi E, Poloni G, et al. Advanced magnetic resonance imaging of neuromyelitis optica: a multiparametric approach. Mult Scler 2012;18:817-24
57. Rocca MA, Agosta F, Mezzapesa DM, et al. Magnetization transfer and diffusion tensor MRI show gray matter damage in neuromyelitis optica. Neurology 2004;62:476-78 (Pubitemid 38200865)
58. Calabrese M, Oh MS, Favaretto A, et al. No MRI evidence of cortical lesions in neuromyelitis optica. Neurology 2012;79:1671-76
59. Liu Y, Duan Y, He Y, et al. Altered topological organization of white matter structural networks in patients with neuromyelitis optica. PLoS One 2012;7:e48846
60. Yu C, Lin F, Li K, et al. Pathogenesis of normal-appearing white matter damage in neuromyelitis optica: diffusion-tensor MR imaging. Radiology 2008;246:222-28 (Pubitemid 350305047)
61. Zhao DD, Zhou HY, Wu QZ, et al. Diffusion tensor imaging characterization of occult brain damage in relapsing neuromyelitis optica using 3.0T magnetic resonance imaging techniques. Neuroimage 2012;59:3173-77
62. Aboul-Enein F, Krssak M, Hoftberger R, et al. Diffuse white matter damage is absent in neuromyelitis optica. AJNR Am J Neuroradiol 2010;31:76-79
63. de Seze J, Blanc F, Kremer S, et al. Magnetic resonance spectroscopy evaluation in patients with neuromyelitis optica. J Neurol Neurosurg Psychiatry 2010;81:409-11
64. Chen X, Zeng C, Luo T, et al. Iron deposition of the deep grey matter in patients with multiple sclerosis and neuromyelitis optica: a control quantitative study by 3D-enhanced susceptibility-weighted angiography (ESWAN). Eur J Radiol 2012;81:e633-e639
65. Duan Y, Liu Y, Liang P, et al. Comparison of grey matter atrophy between patients with neuromyelitis optica and multiple sclerosis: a voxel-based morphometry study. Eur J Radiol 2012;81:e110-e114
66. Lucchinetti CF, Popescu BF, Bunyan RF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011;365:2188-97
67. Calabrese M, Rinaldi F, Grossi P, et al. Cortical pathology and cognitive impairment in multiple sclerosis. Expert Rev Neurother 2011;11:425-32
68. Popescu BF, Parisi JE, Cabrera-Gomez JA, et al. Absence of cortical demyelination in neuromyelitis optica. Neurology 2010;75:2103-09
69. Seewann A, Kooi EJ, Roosendaal SD, et al. Postmortem verification of MS cortical lesion detection with 3D DIR. Neurology 2012;78:302-08
70. Chanson JB, Lamy J, Rousseau F, et al. White matter volume is decreased in the brain of patients with neuromyelitis optica. Eur J Neurol 2013;20:361-67
71. Habib CA, Liu M, Bawany N, et al. Assessing abnormal iron content in the deep gray matter of patients with multiple sclerosis versus healthy controls. AJNR Am J Neuroradiol 2012;33:252-58
72. Zivadinov R, Heininen-Brown M, Schirda CV, et al. Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. Neuroimage 2012;59:331-39
73. Qian W, Chan Q, Mak H, et al. Quantitative assessment of the cervical spinal cord damage in neuromyelitis optica using diffusion tensor imaging at 3 Tesla. J Magn Reson Imaging 2011;33:1312-20
74. Agosta F, Absinta M, Sormani MP, et al. In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study. Brain 2007;130:2211-19 (Pubitemid 47236613)
75. Klawiter EC, Xu J, Naismith RT, et al. Increased radial diffusivity in spinal cord lesions in neuromyelitis optica compared with multiple sclerosis. Mult Scler 2012;18:1259-68
76. Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008;14:1157-74
77. Bedi GS, Brown AD, Delgado SR, et al. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 2011;17:1225-30
78. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:4834-40